Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Blend Therapeutics appoints Mark Iwicki as new CEO
Iwicki comes with more than 23 years of experience in the pharmaceutical industry with experience in managing different stages of drug development and in multiple therapeutic areas. Prior
Iwicki comes with more than 23 years of experience in the pharmaceutical industry with experience in managing different stages of drug development and in multiple therapeutic areas. Prior
Sarepta Therapeutics president and CEO Chris Garabedian said the agreement will lead to development of new treatment options for influenza with new mechanisms of action with limitations of
The patents cover company’s tamper-resistant platforms, designed to resist dose dumping of orally delivered opioids and may sequester and bring down drug release of a drug, which has
According to the deal, Yuhan can leverage CEVEC’s CAP-T and CAP cell expression systems in the production and development of a range of therapeutic proteins. CEVEC CEO Wolfgang
The collaboration will focus on developing Pfizer biologics, leveraging Halozyme’s drug delivery platform Enhanze technology that is based on the company’s recombinant human hyaluronidase enzyme (rHuPH20). Pfizer BioTherapeutics
Fast Track facilitates the development and expedites the review of new drugs intended to serve unmet medical needs in serious or life-threatening conditions. Lexicon Pharmaceuticals senior vice president
As part of the agreement, Cosmo Pharmaceuticals, using its proprietary MMX technology will formulate new human monoclonal antibodies generated by AIMM Therapeutics in an extended release form. AIMM
ImmunoGen president and CEO Daniel Junius said major healthcare companies are interested in developing multiple product candidates with TAP technology. "In recent years, there has been a marked
Established in 1987, HCR is headquartered in Munich, Germany and operates across Europe, Israel and South America in addition to a US office in Princeton, New Jersey. With
The submission was based on a comprehensive clinical development program, in which BEMFOLA had shown to be statistically equivalent to the reference product in patients participating in an